Objective: To explore the effect of secretin to intestinal failure-associated liver disease(IFALD) by supplying physiological doses of secretin to SBS rat model.

Methods: Using 24 male SD rats, we divided them into four groups randomly: SBS+secretin (n=6), SBS+ placebo (n=6), Sham+secretin group (n=6), Sham+placebo (n=6). SBS group underwent 80% intestinal resection and anastomosis. All rats underwent jugular vein cannulation and accepted TPN support for 14 days. Sham group underwent sham resection and anastomosis. We detected blood biochemistry of all rats at preoperative day, 7th day and 14th day. Finally, before rats were sacrificed, we detected bile flow and kept liver tissue specimens.

Results: the ALT (95.28±18.25 U/L), AST (211.96±19.27 U/L), TB (211.96±0.30μmol/L), TBA (23.78±3.59 μmol/L) of SBS+placebo group were significantly higher than those of SBS+secretin group (ALT, 76.35±8.12 U/L;AST, 175.35±7.53 U/L;TB, 175.35±7.53 μmol/L;TBA, 19.59±1.54μmol/L). In addition, the bile flow of SBS+placebo group（6.14±3.04，μml/min） was also lower than that of SBS+secretin group (14.11±4.97μml/min). The pathological score and TUNEL apoptosis semiquantitative of SBS+secretin group were significantly lower than those of SBS+placebo group.

Conclusions: The secretin can significantly decrease IFALD by supplying physiological doses of secretin. This protective effect was associated with the inhibition of hepatocyte apoptosis. The specific mechanism needs further study.